New malaria drug combo shows promise in kids
NCT ID NCT04009343
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how two different malaria drug combinations work in children with uncomplicated malaria in Zambia. The goal was to see how well the drugs clear malaria parasites from the blood and prevent new infections for up to 9 weeks. About 182 children took part, and researchers measured treatment success and reinfection rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 182 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2019
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 59 months
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Weight ≥10 kg * Any indication for malaria diagnostic testing as determined by a treating provider (e.g., fever or history of fever) * P. falciparum parasitemia (by microscopy) of any density not meeting criteria for severe malaria * Ability to swallow oral medication * Ability and willingness of parents or guardians to comply with study protocol for the duration of the study and to comply with the study follow-up visit schedule * Residence within hospital catchment area * Signed informed consent obtained from a legal representative of the participant Exclusion Criteria: * Complicated or severe falciparum malaria as defined by WHO criteria * Hemoglobin concentration \< 7 g/dL * Use of any drug with antimalarial activity within the prior 4 weeks * History of hypersensitivity reaction or intolerance to AL or DP * Co-infection with Plasmodium spp. other than P. falciparum as determined by microscopy * Confirmed or suspected concurrent acute infection other than malaria (e.g. measles, acute lower respiratory tract infection) * Current therapy with QT interval-prolonging agents * Family history of sudden cardiac death or personal history of cardiac disease * Residence outside the study area, or plan to leave the study area * Residence in foster care or otherwise under government supervision * Previous enrollment in the study, or enrollment in any other investigational drug trial during the previous 30 days * Presence of any other condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Uncomplicated falciparum malaria are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tropical Diseases Research Centre
Ndola, Copperbelt, Zambia